You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Claims for Patent: 9,149,477

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,149,477

Title:	5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
Abstract:	Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below:
Inventor(s):	Edward A. Kesicki, Kerry W. Fowler, Danwen Huang, Hua Chee Ooi, Amy Oliver, Kamal Deep PURI, Fuqiang Ruan, Jennifer Treiberg
Assignee:	Gilead Sciences Inc
Application Number:	US14/284,331
Patent Claims:	1. A method of inhibiting phosphatidylinositol 3-kinase activity in a cell with a compound or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, further comprising administering the compound or a pharmaceutically acceptable salt thereof to an individual in need thereof. 3. The method of claim 2, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 4. The method of claim 2, wherein the compound is 5. The method of claim 4, wherein the compound is the S-enantiomer. 6. The method of claim 1, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 7. The method of claim 1, wherein the compound is 8. The method of claim 7, wherein the compound is the S-enantiomer. 9. A method of inhibiting phosphatidylinositol 3-kinase delta activity in a cell, comprising administering to an individual in need thereof the compound or a pharmaceutically acceptable salt thereof. 10. The method of claim 9, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 11. The method of claim 9, wherein the compound is 12. The method of claim 11, wherein the compound is the S-enantiomer.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.